DiaSorin S.p.A. (DIAS.VI)
- Previous Close
99.58 - Open
98.68 - Bid --
- Ask --
- Day's Range
96.08 - 98.68 - 52 Week Range
90.06 - 111.95 - Volume
0 - Avg. Volume
66 - Market Cap (intraday)
5.236B - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
28.51 - EPS (TTM)
3.37 - Earnings Date Jul 28, 2025 - Aug 1, 2025
- Forward Dividend & Yield 1.20 (1.21%)
- Ex-Dividend Date May 19, 2025
- 1y Target Est
110.50
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic LIAISON chemiluminescence analyzers under LIAISON XL and LIAISON XS name; and Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. The company was founded in 1968 and is headquartered in Saluggia, Italy.
int.diasorin.com3,249
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: DIAS.VI
View MorePerformance Overview: DIAS.VI
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is FTSE MIB Index (FTSEMIB.MI) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: DIAS.VI
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: DIAS.VI
View MoreValuation Measures
Market Cap
5.32B
Enterprise Value
5.99B
Trailing P/E
29.58
Forward P/E
22.08
PEG Ratio (5yr expected)
1.44
Price/Sales (ttm)
4.69
Price/Book (mrq)
2.98
Enterprise Value/Revenue
5.05
Enterprise Value/EBITDA
15.01
Financial Highlights
Profitability and Income Statement
Profit Margin
15.87%
Return on Assets (ttm)
5.12%
Return on Equity (ttm)
11.21%
Revenue (ttm)
1.19B
Net Income Avi to Common (ttm)
188.1M
Diluted EPS (ttm)
3.37
Balance Sheet and Cash Flow
Total Cash (mrq)
378.92M
Total Debt/Equity (mrq)
56.40%
Levered Free Cash Flow (ttm)
203.38M